文献速递血液透析通路

药物涂层与非涂层球囊血管成形术在功能不良血液透析通路中的比较效果:Medicare受益人群分析

Comparative effectiveness of drug-coated and uncoated balloon angioplasty in dysfunctional hemodialysis circuits among Medicare beneficiaries.
PubMed 文献 · J Vasc Surg · 2026-06-22

该研究基于美国Medicare全样本数据,分析2018至2024年门诊透析通路血管成形术趋势,并比较2021至2024年动静脉内瘘中药物涂层球囊(DCB)与非涂层球囊(NDCB)的结局。DCB使用比例从2018年第一季度的8.6%升至2024年第四季度的16.1%。

要点

  • Medicare覆盖后DCB使用率从8.6%升至16.1%,但医院间使用差异大。
  • 12个月再干预累积发生率DCB与NDCB无显著差异。
  • DCB与再干预受限平均时间损失减少8.0天相关,支持其延迟再干预的作用。

核心结论

  • 在Medicare受益的血液透析患者中,DCB使用率自2018年起稳步上升但存在选择性。
  • DCB与非涂层球囊相比,12个月再干预累积发生率无差异,但与再干预受限平均时间损失减少相关。
  • 研究结果支持DCB在延迟动静脉内瘘再干预中的作用。

研究设计与样本

  • 使用100% Medicare按服务收费数据,识别2018至2024年349,521例门诊透析通路血管成形术(DCB 35,644例;NDCB 313,877例)用于趋势分析。
  • 比较分析纳入2021至2024年年龄20至80岁、接受动静脉内瘘介入的患者,共64,140例(DCB 12.2%,N=7,813;NDCB 87.8%,N=56,327),采用逆概率加权评估结局。
  • 主要结局为12个月内通路再干预(血管成形术、支架置入或血栓切除术的复合终点)。

主要发现

  • DCB使用比例从2018年第一季度的8.6%上升至2024年第四季度的16.1%(差值7.5%)。
  • 2023至2024年间,30.0%的医院在超过30.0%的病例中使用DCB。
  • 比较分析中,平均年龄62.6(12.4)岁,女性占38.7%,加权后基线特征无残留不平衡。

临床怎么用

  • 对于血液透析患者动静脉内瘘狭窄,DCB可作为延迟再干预的选项之一。
  • 临床决策需结合医院DCB使用经验和患者个体情况,因再干预累积发生率无差异。
  • DCB的使用应关注其减少再干预时间损失的潜在获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The durability of percutaneous balloon angioplasty for arteriovenous fistula stenosis is short-lived. In randomized controlled trials, drug-coated balloons (DCBs) have shown promise in reducing reintervention compared with uncoated balloons (NDCBs). However, DCB device uptake and outcomes are poorly described. We assessed temporal trends, practice variation, and outcomes of outpatient drug-coated vs uncoated balloon angioplasty for arteriovenous fistulas in the United States. METHODS: Using a 100% sample of Medicare fee-for-service data, we identified 349,521 outpatient dialysis access angioplasty procedures (DCB = 35,644; NDCB = 313,877) from 2018 to 2024 for trend analyses. For comparative analyses, we further identified patients aged 20 to 80 years who underwent intervention on an arteriovenous fistula from 2021 to 2024. Outcomes of drug-coated vs uncoated balloon angioplasty were assessed after inverse probability weighting. The primary outcome was access reintervention (a composite of angioplasty, stenting, or thrombectomy) through 12 months. RESULTS: Proportional DCB use increased steadily after Medicare coverage in 2018 Q1 (8.6%), reaching 16.1% in 2024 Q4 (difference, 7.5%). During 2023-2024, 30.0% of hospitals used DCBs in >30.0% of cases. For comparative analyses, a total of 64,140 procedures (DCB 12.2%, N = 7813; NDCB 87.8%, N = 56,327) were included. The mean age was 62.6 (12.4) years, 38.7% were female, and, following weighting, there was no residual imbalance in baseline characteristics. Through 12 months, there was no difference in cumulative incidence of reintervention (adjusted cumulative incidence function DCB 57.7% vs NDCB 56.9%, P = .22), but DCBs were associated with reduced restricted mean time lost to reintervention (adjusted restricted mean time lost difference: -8.0 days, 95% confidence interval: -11.1 to -4.9 days, P < .0001). CONCLUSIONS: DCB use has risen steadily but selectively since Medicare coverage. DCB use was associated with increased reintervention-free time through 12 months. These findings support the role of DCBs in delaying arteriovenous fistula reintervention among hemodialysis patients.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Smith H, Li S, Salomon B, et al. Comparative effectiveness of drug-coated and uncoated balloon angioplasty in dysfunctional hemodialysis circuits among Medicare beneficiaries. J Vasc Surg. 2026. PMID: 42331153. doi:10.1016/j.jvs.2026.06.061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。